200 related articles for article (PubMed ID: 30243468)
1. Use of hyperthermia versus normothermia during intraperitoneal chemoperfusion with oxaliplatin for colorectal peritoneal carcinomatosis: A propensity score matched analysis.
Gremonprez F; Gossye H; Ceelen W
Eur J Surg Oncol; 2019 Mar; 45(3):366-370. PubMed ID: 30243468
[TBL] [Abstract][Full Text] [Related]
2. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
3. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
5. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
6. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
7. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
8. Impact of Perfusate Concentration on Hyperthermic Intraperitoneal Chemotherapy Efficacy and Toxicity in a Rodent Model.
Liesenfeld LF; Hillebrecht HC; Klose J; Schmidt T; Schneider M
J Surg Res; 2020 Sep; 253():262-271. PubMed ID: 32388389
[TBL] [Abstract][Full Text] [Related]
9. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M
World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
Leung V; Huo YR; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis.
Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH
Ann Surg Oncol; 2016 Mar; 23(3):833-41. PubMed ID: 26442921
[TBL] [Abstract][Full Text] [Related]
12. HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road?
Ceelen W
Eur J Surg Oncol; 2019 Mar; 45(3):400-402. PubMed ID: 30392745
[TBL] [Abstract][Full Text] [Related]
13. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin.
Ceelen W; De Somer F; Van Nieuwenhove Y; Vande Putte D; Pattyn P
Eur J Surg Oncol; 2013 Jul; 39(7):754-9. PubMed ID: 22878060
[TBL] [Abstract][Full Text] [Related]
14. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer.
Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L
J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983
[TBL] [Abstract][Full Text] [Related]
16. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O
Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385
[TBL] [Abstract][Full Text] [Related]
19. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis.
van Oudheusden TR; Braam HJ; Nienhuijs SW; Wiezer MJ; van Ramshorst B; Luyer MD; Lemmens VE; de Hingh IH
Ann Surg Oncol; 2014 Aug; 21(8):2621-6. PubMed ID: 24671638
[TBL] [Abstract][Full Text] [Related]
20. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]